Nimish originally joined Venrock in 2013 and has been investing in public and private healthcare companies since 2010. He works predominantly on Venrock’s public and cross-over biotech funds.
He is currently a Board Observer for Dianthus. He previously served as a Board Director for InstilBio (NASDAQ: TIL) and Board Observer for LianBio (NASDAQ: LIAN), Biohaven Pharmaceuticals (NYSE: BHVN) and Viridian Therapeutics (NASDAQ: VRDN).
Nimish received his BS in pharmacy with honors from Rutgers College of Pharmacy, MPH from the Mailman School of Public Health at Columbia University, and MBA from Columbia Business School. He is a member of the Columbia Business School Healthcare and Pharmaceutical Management Advisory Board.